Enquiry

PSMA 617

Code: PS 0090

Synonyms: 2-[3-(1-Carboxy-5-{3-naphthalen-2-yl-2-[(4-{[2-(4,7,10-tris-carboxymethyl-1,4,7,10-tetraaza-cyclododec-1-yl)-acetylamino]-methyl}-cyclohexanecarbonyl)-amino]-propionylamino}-pentyl)-ureido]-pentanedioic acid, PSMA617 TFA; PSMA617 triflouroacetic acid salt; vipivotide tetraxetan; DKFZ-PSMa-617

puriss

C49H71N9O16.CF3COOH

29420090

95%+

1042.14 (net)

Vial / Bottle
18%
puriss

C49H71N9O16.CF3COOH

29420090

95%+

1042.14 (net)

Vial / Bottle

18%
PackingsPrice (INR)
1 mg 390690.00
5 mg POR
1 gm POR
Packings
Enquire
Properties
95%+

Powder

Colourless to white to off-white

1041.5

-20 °C

Description

PSMA-617 - a novel theranostic PSMA inhibitor for both diagnosis and endoradiotherapy of prostate cancer.

Application

PS 0090 (OTTO) PSMA 617 Cas 1702967-37-0 - used in chemical research.

Safety Information

Safety Information for this product is unavailable at this time.

Documentation

Certificate Of Analysis

(For eg. B 1615-0108)

Other Documents

For any quries, please write to us at

qc@ottokemi.com
Technical Services

Our team of R&D Experts and Scientists have expertise in all areas of research of Lab Chemicals, Nano Technology, Life Science, Custom Synthesis, Chromatography, and many others.

Enquire Now

DisclaimerThe above particulars do not release the customer from the obligation to carry out an inspection of goods received.
Not for medical, household or any other uses, for lab use only, Please test before use.


PackingsPrice (INR)
1 mg 390690.00
5 mg POR
1 gm POR